April 26, 2024
Bio
SK Biopharma develops AI drug design platform
[THE INVESTOR] SK Biopharmaceuticals said on Oct. 15 it has developed a drug design platform based on artificial intelligence which will help it reduce research costs while speeding up the development of new therapies.
The biotech firm has partnered with SK C&C, IT firm and SK group’s holding company, for AI algorithm that enables the development of new therapies.
“The unique platform has opened a new pathway for next-generation new drug development by pushing boundaries of existing ones that mainly play a predictor function to actually design drugs,” Maeng Cheol-young, who leads the company’s digital health care task force said.
According to the firm, the platform consists of two models. One predicts drug properties involving distribution, metabolism, excretion and toxicity, a critical step of the drug design process as these properties account for the failure of about 60 percent of all drugs in the clinical phases
The other model designs new substances by analyzing hidden patterns and characteristics based on data from the prediction process.
“We expect the platform will accelerate drug discovery process and lead to significant savings in research and development costs,” Maeng said.
By Park Han-na (hnpark@heraldcorp.com)
The biotech firm has partnered with SK C&C, IT firm and SK group’s holding company, for AI algorithm that enables the development of new therapies.
“The unique platform has opened a new pathway for next-generation new drug development by pushing boundaries of existing ones that mainly play a predictor function to actually design drugs,” Maeng Cheol-young, who leads the company’s digital health care task force said.
According to the firm, the platform consists of two models. One predicts drug properties involving distribution, metabolism, excretion and toxicity, a critical step of the drug design process as these properties account for the failure of about 60 percent of all drugs in the clinical phases
The other model designs new substances by analyzing hidden patterns and characteristics based on data from the prediction process.
“We expect the platform will accelerate drug discovery process and lead to significant savings in research and development costs,” Maeng said.
By Park Han-na (hnpark@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
